


# Valbenazine

12/19

**ALTERNATE NAMES:** [(2R,3R,11bR)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-yl] (2S)-2-amino-3-methylbutanoate; NBI 98854; Ingrezza; L-Valine, (2R,3R,11bR)-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester

**CATALOG #:** B2954-5 5 mg  
B2954-25 25 mg

## STRUCTURE:



**MOLECULAR FORMULA:** C<sub>24</sub>H<sub>38</sub>N<sub>2</sub>O<sub>4</sub>

**MOLECULAR WEIGHT:** 418.57

**CAS NUMBER:** 1025504-45-3

**APPEARANCE:** Solid

**PURITY:** ≥98%

**SOLUBILITY:** ~25 mg/ml in DMSO  
~10 mg/ml in Ethanol  
~30 mg/ml in DMF

**DESCRIPTION:** Valbenazine is an inhibitor of vesicular monoamine transporter 2 (VMAT2). VMAT2 plays an important role in the packaging of monoamines into presynaptic vesicles. Valbenazine shows K<sub>i</sub> values of 110 and 150 nM in rat striatum homogenates and human platelets, respectively. It is selective for VMAT2 over serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, and 5-HT2B and dopamine D1 and D2 receptors. It is used for the treatment of tardive dyskinesia.

**STORAGE TEMPERATURE:** -20°C

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

**REFERENCE:** Grigoriadis, D.E., Smith, E., Hoare, S.R.J., et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J. Pharmacol. Exp. Ther. 361(3), 454-461 (2017).

## RELATED PRODUCTS:

Thioridazine Hydrochloride (Cat. No. B1581)  
Chlorpromazine Hydrochloride (Cat. No. B1992)  
Eltoprazine hydrochloride (Cat. No. B2301)  
Aripiprazole (Cat. No. B1186)  
Sertraline (hydrochloride) (Cat. No. B2393)

**DISCLAIMER:** **FOR RESEARCH USE ONLY! Not to be used on humans.**